Bristol-myers Squibb

This early-stage study tested a new drug (BMS-986258) alone or with another cancer drug (nivolumab) in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and side effects. The study was terminated, meaning it stopped early,…

This study tested whether adding the immunotherapy drug nivolumab to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the trial was stopped early. The goal was to see if the combination delayed c…

This study tested whether a combination of two immunotherapy drugs (nivolumab and relatlimab) works better than nivolumab alone to prevent melanoma from coming back after surgery. It involved over 1,000 adults and teens with stage III or IV melanoma that had been completely remov…

This study looked at how safe and effective ozanimod is for people with moderate to severe ulcerative colitis, and how it affects their quality of life. About 139 participants were planned, but the study was stopped early. The goal was to see if the drug could reduce symptoms lik…

This study tested a drug called MORAb-202 in people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had spread and stopped responding to other treatments. The drug works like a guided missile, targeting a protein called folate receptor alpha o…

This early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in 56 people with acute myeloid leukemia or myelodysplastic syndromes that had come back or not responded to treatment. The main goal was to check safety and find the right dose. The study…

This study tested the drug deucravacitinib in 130 adults with psoriasis on their palms, soles, and genitals. The goal was to see if it could safely improve skin symptoms like redness and scaling. The trial was terminated early, so results are limited.

This study aimed to understand how moderate or severe liver impairment changes the way the body processes the cancer drug CC-486 (Onureg) in adults with certain blood cancers. Researchers planned to compare drug levels and safety between people with and without liver problems. On…